TILS (Shanghai Gencells Therapeutics)

自体天然肿瘤浸润淋巴细胞

Report date: 2026/05/06 20:02:28

Base Information

Drug NameTILS (Shanghai Gencells Therapeutics)
Drug Alias NameTumor infiltrating lymphocytes (Shanghai Gencells Therapeutics)Autologous tumour infiltrating lymphocytes (Shanghai Juncell Therapeutics)GC 101 TILGC101 TIL
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsGenital Neoplasms, Female +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Junsai Biological Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Junsai Biological Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsGenital Neoplasms, Female +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A